Scholarly article on topic 'Modulation of myocardial contraction by peroxynitrite'

Modulation of myocardial contraction by peroxynitrite Academic research paper on "Basic medicine"

0
0
Share paper
Academic journal
Frontiers in Physiology
OECD Field of science
Keywords
{""}

Academic research paper on topic "Modulation of myocardial contraction by peroxynitrite"

frontier

IN STRIATED MUSCLE PHYSIOLOGY

Modulation of Myocardial Contraction by Peroxynitrite

Mark Kohr, Steve Roof, Jay Zweier and Mark T Ziolo

Journal Name: ISSN:

Article type: Received on: Accepted on:

Provisional PDF published on: Frontiers website link: Citation:

Article URL:

Copyright statement:

Frontiers in Physiology

1664-042X

Review Article

08 Oct 2012

26 Nov 2012

26 Nov 2012

www.frontiersin.org

Kohr M, Roof S, Zweier J and Ziolo MT(2012) Modulation of Myocardial Contraction by Peroxynitrite. Front. Physio. 3:468. doi:10.3389/fphys.2012.00468

http://www.frontiersin.org/Journal/Abstract.aspx?s=1018& name=striated%20muscle%20physiology&ART D0I=10.3389 /fphys.2012.00468

(If clicking on the link doesn't work, try copying and pasting it into your browser.)

© 2012 Kohr, Roof, Zweier and Ziolo. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

This Provisional PDF corresponds to the article as it appeared upon acceptance, after rigorous peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon.

10 11 12

20 21 22

Modulation of Myocardial Contraction by Peroxynitrite

Mark J Kohr1,3, Steve R Roof1, Jay L Zweier2, Mark T Ziolo1*

department of Physiology & Cell Biology, 2Department of Internal Medicine: Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH 43210, USA. 3Division of Cardiovascular Pathology, Department of Pathology, Johns Hopkins University, Baltimore, MD 21205

Running Head: ONOO- and myocardial contraction

Word count:

Corresponding author:

Mark T Ziolo

Department of Physiology & Cell Biology

The Ohio State University

304 Hamilton Hall

1645 Neil Avenue

Columbus, OH 43210

Telephone: 614-688-7905 Fax:614-688-7999 E-mail: ziolo.1@osu.edu

1 Abstract

2 Peroxynitrite is a potent oxidant that is quickly emerging as a crucial modulator of myocardial

3 function. This review will focus on the regulation of myocardial contraction by peroxynitrite

4 during health and disease, with a specific emphasis on cardiomyocyte Ca2+ handling, proposed

5 signaling pathways, and protein end-targets.

8 Key words: myocyte, peroxynitrite, nitric oxide synthase, Ca2+, cAMP-dependent protein kinase,

9 protein phosphatase 2a 10

1 The heart plays a vital role in the cardiovascular system by providing the specialized

2 tissues and organs of the body with a continual supply of oxygen and other essential nutrients.

3 Modulation of myocardial contraction allows the heart to meet the demands of the body despite

4 continual changes in metabolism. This modulation occurs at several different levels, including

5 the level of the ventricular cardiomyocyte.

7 Excitation-contraction Coupling

8 Cardiomyocyte contraction occurs via a process termed excitation-contraction coupling,

9 in which the electrical activity of the heart is translated into cardiomyocyte contraction (Bers,

10 2001;, 2002). This process commences with the cardiac action potential and the depolarization of

11 the myocyte membrane, which leads to the opening of L-type Ca2+ channels (Bers, 2001;, 2002).

12 This causes an influx of Ca2+ into the myocyte via the L-type Ca2+ current (ICa), and

13 subsequently triggers the opening of the sarcoplasmic reticulum Ca2+-release channels or

14 ryanodine receptors (RyR). This results in an efflux of Ca2+ from the sarcoplasmic reticulum

15 (SR), which is the major Ca2+ store in the cardiomyocyte, in a process termed Ca2+-induced Ca2+-

16 release. This process initiates the upstroke of the myocyte [Ca2+]i transient and this Ca2+ is now

17 available for myocyte contraction. SR Ca2+ load, which represents the Ca2+ available for release

18 from the SR, is a critical determinant of [Ca2+]i transient amplitude and thus myocyte contraction

19 (Bassani et al., 1995;Trafford et al., 1995).

21 The [Ca2+]i transient is responsible for the activation of cardiomyocyte contraction or

22 shortening. When [Ca2+]i increases within the cardiomyocyte, this Ca2+ diffuses to the

23 myofilaments and binds to troponin C (TnC) (Davis and Tikunova, 2008). This induces a strong

24 interaction between TnC and troponin I (TnI), effectively destabilizing the interaction between

25 Tnl and actin. This shifts the troponin-tropomyosin complex in such a way as to allow the

26 myosin head to bind directly to actin, thus leading to the formation of a myosin crossbridge.

27 Provided that ATP is readily available to the myosin head, myocyte force production and/or

28 shortening ensues until Ca2+ is no longer bound to TnC.

30 Relaxation is initiated by the decline of the [Ca2+]i transient, which is primarily mediated

31 by the SR Ca2+-ATPase/phospholamban complex (SERCA/PLB) and the Na+/Ca2+ exchanger

32 (NCX) (Bers, 2001;, 2002). The SERCA/PLB complex serves to re-sequester Ca2+ into the SR,

33 while NCX directly extrudes Ca2+ into the extracellular space. PLB is a phosphoprotein that

34 plays a critical role in the decline of the [Ca2+]i transient by regulating the uptake of Ca2+ by

35 SERCA. Under basal conditions, PLB remains hypophosphorylated and serves to inhibit the

36 uptake of Ca2+ by SERCA. This inhibition can be relieved upon PLB Serine16 phosphorylation

37 by protein kinase A (PKA), thus allowing greater uptake of Ca2+ into the SR (Chu et al.,

38 2000;Hagemann and Xiao, 2002;Mattiazzi et al., 2006). There are two main serine/threonine

39 protein phosphatases that dephosphorylate PLB, protein phosphatase 1 (PP1) and protein

40 phosphatase 2a (PP2a) (MacDougall et al., 1991).

42 Modulation of excitation-contraction coupling

43 Since every cardiomyocyte is recruited to contract with each heartbeat, numerous

44 endogenous systems have evolved to effectively regulate the ventricular myocyte contractile

45 state by modulating excitation-contraction coupling. For example, stimulation of the P-

46 adrenergic receptor (P-AR) pathway results in positive inotropic and lusitropic effects via

modulation of key excitation-contraction coupling proteins (Bers and Ziolo, 2001). Activation of the P-AR signaling pathway transpires with binding of an agonist (e.g. epinephrine, isoproterenol) to the receptor, which results in the dissociation of the Gsa subunit. Gsa induces cAMP production via adenylate cyclase (AC). Increased cAMP then activates the cAMP-dependent protein kinase or PKA, which phosphorylates many different targets in the cardiomyocyte, including ICa, RyR, TnI, and PLB. The end result is increased Ca2+ influx, increased SR Ca2+ uptake, load, and release, and decreased myofilament Ca2+ sensitivity. PLB phosphorylation at Serine16 by PKA is one of the primary mechanisms responsible for the observed positive inotropic and lusitropic effects of P-AR stimulation (Chu et al., 2000;Li et al., 2000;Roof et al., 2011;Roof et al., 2012). Therefore, altering PLB phosphorylation levels will lead to drastic changes in myocardial contraction and relaxation. Since the P-AR pathway is perhaps the most important regulator of myocardial contractility, this pathway itself is modulated by other endogenous systems such as reactive nitrogen species.

Reactive nitrogen species

Reactive nitrogen species (RNS) are quickly emerging as crucial modulators of myocardial contraction during health and disease (Pacher et al., 2007). Alterations in the production of these reactive species may be responsible for part of the dysfunction that is observed during many pathophysiological conditions of the myocardium and may represent novel therapeutic targets. However, the modulation of myocardial function by RNS is a relatively new field and many questions remain unanswered. For example, studies have yet to conclusively determine whether this dysfunction results from the loss of endogenous RNS production (i.e., nitric oxide) or from the production of supraphysiological levels of reactive species. In all likelihood, this dysfunction stems from the partial loss of localized RNS signaling coupled with an increase in the production of more reactive species, including peroxynitrite. Indeed, this appears to be the case (Feldman et al., 2008;Ziolo et al., 2008).

Nitric oxide (NO) is a well known modulator of many physiological processes, including neural transmission and the regulation of blood pressure. However, NO is also surfacing as a key modulator of myocardial function by serving as a regulator of excitation-contraction coupling (Ziolo et al., 2001b;Ziolo et al., 2004;Wang et al., 2008a;Wang et al., 2008b;Wang et al., 2009;Wang et al., 2010) and p-AR signaling (Balligand et al., 1993;Ziolo et al., 2001c). NO is produced endogenously within the myocardium by three distinct isoforms of NO synthase (NOS) (Ziolo and Bers, 2003). Neuronal NOS (NOS1) and endothelial NOS (NOS3) are constitutively expressed within cardiomyocytes. NOS1 and NOS3 produce low amounts of NO in phase with the myocyte [Ca2+]i transient. Inducible NOS (NOS2), on the other hand, is only expressed within cardiomyocytes during inflammatory responses which occur during many pathophysiological conditions of the myocardium. NOS2 produces much higher amounts of NO compared to constitutive isoforms, and is [Ca2+]i independent (Schulz et al., 1992;Ziolo et al., 1998;Ziolo et al., 2001a).

NO is known to signal through at least two distinct signaling pathways: cGMP-dependent and cGMP-independent (Ziolo, 2008). cGMP-dependent signaling occurs through the activation of guanylate cyclase and protein kinase G (PKG), while cGMP-independent signaling primarily occurs via direct protein modification (e.g. ^-nitrosylation) (Martinez-Ruiz and Lamas, 2004;Hess et al., 2005;Handy and Loscalzo, 2006;Kohr et al., 2011b). NO has also been shown

1 to directly activate adenylate cyclase independent of P-AR activation, thus resulting in positive

2 inotropic effects via increased cAMP production and PKA activation (Vila-Petroff et al., 1999).

3 NO also signals by coupling to other reactive signaling species (e.g., superoxide anion) to form

4 related congeners, such as peroxynitrite.

6 Peroxynitrite

7 Peroxynitrite (ONOO-) is a potent oxidant that is formed upon the reaction of NO and

8 superoxide. This reaction occurs with an extremely high rate constant, making the formation of

9 peroxynitrite quite favorable (Huie and Padmaja, 1993;Beckman and Koppenol, 1996). Although

10 peroxynitrite is a highly reactive species, it is still capable of diffusing through biological

11 membranes and interacting with intracellular constituents (Denicola et al., 1998). Under

12 physiological conditions, peroxynitrite production remains low and potential oxidative damage is

13 reduced via endogenous cellular antioxidant defenses (Radi et al., 2002a;Radi et al., 2002b). Low

14 levels of peroxynitrite may also serve to modulate various intracellular signaling pathways. In

15 fact, peroxynitrite appears to play a role in the regulation of many important physiological

16 processes. For example, peroxynitrite has been demonstrated to modulate T cell proliferation

17 (Brito et al., 1999;Vig et al., 2004), platelet aggregation (Schildknecht et al., 2008), and

18 neutrophil adhesion (Zouki et al., 2001). Peroxynitrite is thought to mediate these physiological

19 processes by targeting various proteins and/or signaling pathways, including receptor tyrosine

20 kinases, mitogen-activated protein kinases, phosphoinositide 3-kinase/protein kinase B (Akt),

21 protein kinase C, and nuclear factor kB (Pacher et al., 2007).

23 The production of peroxynitrite increases greatly during the pathogenesis of numerous

24 disorders, such as cerebral ischemia-reperfusion (Thiyagarajan et al., 2004;Dhar et al., 2006),

25 myocardial ischemia-reperfusion (Wang and Zweier, 1996;Cheung et al., 2000), heart failure

26 (Ferdinandy et al., 2000;Mihm et al., 2001;Zhang et al., 2007), atherosclerosis (Buttery et al.,

27 1996;Luoma et al., 1998), diabetes (Suarez-Pinzon et al., 1997;Suarez-Pinzon et al., 2001), and

28 septicemia (Bhattacharyya et al., 2004). Although peroxynitrite production plays a critical role

29 for neutrophils and macrophages in microbial defense (MacMicking et al., 1997;Nathan and

30 Shiloh, 2000), supraphysiological levels of peroxynitrite are almost always detrimental to

31 cellular function. Peroxynitrite exerts damaging effects by altering protein structure and function

32 via irreversible nitration to tyrosine residues and cysteine oxidation (Kamat, 2006;Pacher et al.,

33 2007). Peroxynitrite can also exert effects by reacting with transition metal centers, including

34 heme prosthetic groups (Pietraforte et al., 2001;Lin et al., 2007) and zinc-thiolate motifs (Crow

35 et al., 1995;Zou et al., 2004), thus resulting in the inactivation of many enzymes. NOS3, an

36 enzyme which exerts many cardioprotective effects (Janssens et al., 2004;Buys et al., 2007;Wang

37 et al., 2008b;Wang et al., 2012), can be inhibited upon exposure to high levels of peroxynitrite

38 (Chen et al.;Zou et al., 2004). Additionally, hydroxylation of ring systems (Szabo et al.,

39 1997;Tuo et al., 1998), DNA strand breakage (Szabo et al., 1996;Szabo et al., 1997), and lipid

40 peroxidation (Radi et al., 1991a;b) can be induced by peroxynitrite. Apoptosis and necrosis can

41 also be triggered upon peroxynitrite exposure (Gilad et al., 1997;Arstall et al., 1999;Pacher et al.,

42 2002;Levrand et al., 2006). Moreover, peroxynitrite will react with other molecules, such as

43 carbon dioxide (CO2), to form additional reactive species (i.e., nitrosoperoxycarbonate) (Uppu

44 and Pryor, 1996). Increased peroxynitrite production is further compounded by the depletion of

45 endogenous antioxidant pools, including glutathione (GSH), which is a major scavenger of

reactive oxygen and nitrogen species (Valko et al., 2007). The production of peroxynitrite occurs endogenously in several different ways.

Peroxynitrite can be formed endogenously within the ventricular cardiomyocyte through various routes under physiological and pathophysiological conditions. A major source for the production of peroxynitrite includes the NOS isoforms (namely NOS1 and NOS2) and via non-classical pathways (namely nitroxyl).

NOS1 has been shown to co-immunoprecipitate with xanthine oxidoreductase (Khan et al., 2004), a superoxide producing enzyme. This interaction between NOS1 and xanthine oxidoreductase will lead to the physiological production of low levels of peroxynitrite. Additionally, NOS1 can potentially produce both NO and superoxide (Pou et al., 1992;Xia et al., 1996), although this is more likely to occur with NOS uncoupling during various disease states (Sun et al., 2008). NOS uncoupling will increase superoxide production by NOS1, while decreasing NO production. NOS1 is considered to be a physiological regulator of myocardial function by increasing basal contractility, the force-frequency response, and the response to PAR stimulation (Barouch et al., 2002;Khan et al., 2003;Vandsburger et al., 2007;Wang et al., 2008a;Wang et al., 2010).

NOS2 is a high output NOS isoform and can readily become uncoupled upon depletion of the cofactors necessary for NO production, thus leading to the production of both NO and superoxide (Xia and Zweier, 1997;Mungrue et al., 2002). Additionally, NADPH oxidase and xanthine oxidoreductase can increase superoxide production under the same pathophysiological conditions in which NOS2 is expressed (Heymes et al., 2003;Minhas et al., 2006). This will lead to the production of supraphysiological levels of peroxynitrite. NOS2 is considered to be a pathophysiological regulator of myocardial function by decreasing the response to P-AR stimulation (Drexler et al., 1998;Ziolo et al., 2001b;Ziolo et al., 2004).

In addition to the NO produced via NOS1 and NOS2, additional sources of peroxynitrite include nitroxyl, the one electron reduction production of NO (Kirsch and de Groot, 2002). Endogenous production of nitroxyl within cardiomyocytes may occur through various routes, including via hydrogen atom extraction by NO (Akhtar et al., 1985). NOS1 also remains a potential source for the production of nitroxyl (Schmidt et al., 1996;Ishimura et al., 2005). Therefore, the reaction of nitroxyl with O2 will lead to the production of low levels of peroxynitrite.

Peroxynitrite and cardiomyocyte contraction

Recent work has now demonstrated that peroxynitrite is able to modulate excitation-contraction coupling, and hence contractility. In the myocardium, peroxynitrite has been demonstrated to exert biphasic effects on cardiomyocyte contraction. More specifically, low levels of peroxynitrite (which occurs under physiological conditions) have been shown to produce positive inotropic effects on cardiomyocyte function. Conversely, high levels of peroxynitrite (which occurs under pathophysiological conditions) are extremely detrimental to myocardial function by decreasing cardiomyocyte contraction.

Physiological regulation of cardiomyocyte contraction by peroxynitrite

Many studies have shown that low levels of peroxynitrite induce positive inotropic effects on basal myocardial function. Chesnais et al. demonstrated peroxynitrite to increase force production in frog atrial and ventricular fibers using authentic peroxynitrite, as well as the peroxynitrite donor SIN-1 (Chesnais et al., 1999a;b). Paolocci et al. confirmed this positive effect on basal function in mammalian ex vivo myocardial preparations using SIN-1 (Paolocci et al., 2000). Interestingly, this effect was reversed with GSH and occurred independently from global changes in cAMP and cGMP levels. Furthermore, we demonstrated that a low concentration of peroxynitrite increased basal and submaximal P-AR-stimulated contraction in isolated cardiomyocytes (Kohr et al., 2008a). We next investigated the molecular mechanisms of this peroxynitrite-induced increase in basal contraction and found that it was dependent upon PLB. That is, peroxynitrite had no effect on basal contraction in PLB knockout myocytes. Further explorations demonstrated that peroxynitrite resulted in the enhancement of PLB Serine16 (the PKA site) phosphorylation (Kohr et al., 2010) and was abolished upon inhibition of PKA with KT5720 (Kohr et al., 2010). Low peroxynitrite also increased PKA activity in cardiac homogenates and in purified preparations of PKA containing both the regulatory and catalytic subunits of PKA, indicating that peroxynitrite induces a direct, cAMP-independent activation of PKA. This direct effect may occur via ^-nitrosylation, ^-glutathiolation and/or cysteine oxidation (Ferdinandy, 2006;Pacher et al., 2007), as PKA has several cysteine residues which are susceptible to these types of modifications (Brennan et al., 2006;Burgoyne and Eaton, 2009;Kohr et al., 2011a). Thus, low levels of peroxynitrite shift the kinase/phosphatase balance leading to increased PLB phosphorylation. Interestingly, the effect of low peroxynitrite on submaximal P-AR stimulated contraction was still observed in PLB knockout myocytes, suggesting another protein target. A recent study demonstrated that PKA phosphorylation of RyR contributes to the inotropic effect of P-AR stimulation using low dose of isoproterenol (Shan et al., 2010). Thus, peroxynitrite mediated activation of PKA may also lead to RyR phosphorylation contributing to the contractile effects of P-AR stimulation. Non PKA-mediated effects of peroxynitrite have also been reported such as ^-nitrosylation of SERCA2a, which increases Ca2+ uptake and relaxation (Bencsik et al., 2008).

We previously demonstrated in healthy ventricular cardiomyocytes that NOS1 signals partly through the production of peroxynitrite (Wang et al., 2008a). Additionally, we and others have shown that NOS1 signaling increases myocardial contraction (basal, force-frequency response and P-AR-stimulated contraction) (Barouch et al., 2002;Khan et al., 2004;Wang et al., 2008a), parameters that can be considered physiologic. These effects are consistent with the positive inotropic effects of peroxynitrite (i.e., peroxynitrite increased basal and submaximal PAR-stimulated contraction). Interestingly, NOS1"" myocytes exhibit reduced basal contraction and a diminished response to P-AR stimulation compared to wildtype (Barouch et al., 2002;Khan et al., 2004;Wang et al., 2008a), which we and others demonstrated to occur in part through a reduction in RyR activity (Wang et al., 2010) and PLB Serine16 phosphorylation (Wang et al., 2008a;Zhang et al., 2008). This is also consistent with the PLB and RyR dependent effects of low peroxynitrite (Kohr et al., 2008a). In addition, NOS1 has been shown to potentially modulate PKA activity, as PKA inhibition decreased PLB Serine 16 phosphorylation and the rate of relaxation in wildtype myocytes, but had no effect in NOS1"" myocytes (Zhang et al., 2008). Therefore, the physiological production of low levels of peroxynitrite may serve to maintain and/or increase basal and P-AR-stimulated myocyte contraction, in part, through a direct, cAMP-independent activation of PKA. Further, the loss of localized NOS 1-mediated peroxynitrite

1 production under certain disease states where NOS1 translocates to the sarcolemma (Damy et al.,

2 2003;Damy et al., 2004), may result in decreased myocyte contraction similar to that observed

3 with the knockout of NOS1.

5 Pathophysiological regulation of cardiomyocyte contraction by peroxynitrite

6 At high concentrations, peroxynitrite is detrimental to myocardial function. Studies

7 examining high levels of peroxynitrite have demonstrated dysfunctional effects via direct

8 exposure or using peroxynitrite donors (Lopez et al., 1997;Ma et al., 1997;Ferdinandy et al.,

9 1999;Ferdinandy et al., 2000;Katori et al., 2006). Additionally, we have demonstrated a NOS2-

10 induced reduction in P-AR-stimulated RyR activity through a cGMP-independent mechanism,

11 likely via peroxynitrite (Ziolo et al., 2001b). Further, we and others have shown a reduction in P-

12 AR-stimulated contraction upon exposure to a high concentration of SIN-1 in isolated

13 cardiomyocytes (Stojanovic et al., 2001;Yin et al., 2002). We demonstrated that this SIN-1-

14 induced decrease in P-AR-stimulated contraction occurred via peroxynitrite formation and was

15 also dependent upon PLB. However unlike low peroxynitrite, high peroxynitrite results in a

16 reduction in PKA-dependent PLB Serine16 phosphorylation (Kohr et al., 2008b). Upon further

17 examination of this signaling pathway, we determined that high peroxynitrite increased

18 phosphatase activity in cardiac homogenates (low peroxynitrite had no effect on phosphatase

19 activity). Interestingly, it appears that peroxynitrite selectively targets PP2a as we observed an

20 increased interaction between PLB and PP2a (but not PP1) with peroxynitrite (Kohr et al., 2009).

21 This reversible effect may occur through a protein intermediate or from the direct modification

22 of PP2a by peroxynitrite via ^-nitrosylation, ^-glutathiolation and/or cysteine oxidation

23 (Ferdinandy, 2006;Pacher et al., 2007). PP2a has several cysteine residues which are susceptible

24 to these types of modifications (Sommer et al., 2002). Consistent with our results, peroxynitrite

25 has been shown to directly activate PP2a via tyrosine nitration in endothelial cells (Wu and

26 Wilson, 2009). Thus, high levels of peroxynitrite shift the kinase/phosphatase balance leading to

27 decreased PLB phosphorylation. While PP2A also modulates RyR phosphorylation (Terentyev et

28 al., 2003), we did not observe any effects of high peroxynitrite on the P-AR response in PLB

29 knockout myocytes, which suggests that this may be a compartmentalized effect targeted to PLB.

31 The production of high levels of peroxynitrite in the myocardium is often associated with

32 the expression of NOS2 (Xia et al., 1998;Mungrue et al., 2002) and increased ROS production

33 via NADPH oxidase (Byrne et al., 2003;Heymes et al., 2003) and xanthine oxidase (Tziomalos

34 and Hare, 2009). Specifically in heart failure, studies have shown an increase in peroxynitrite

35 production (Ferdinandy et al., 2000;Mihm et al., 2001;Zhang et al., 2007), as well as a

36 diminished response to P-AR stimulation (Houser et al., 2000). We have previously

37 demonstrated that myocytes isolated from failing human hearts expressing NOS2, displayed a

38 blunted response to P-AR stimulation (Ziolo et al., 2004). This dysfunction could be reversed

39 upon acute inhibition of NOS2, such that peak [Ca2+]i and cell shortening were significantly

40 increased. This same functional phenomenon was observed with high peroxynitrite (i.e.,

41 peroxynitrite decreased contraction during P-AR stimulation). Interestingly, PP2a activity has

42 been shown to be increased in heart failure (Boknik et al., 2000), while PLB Serine16

43 phosphorylation has been shown to be decreased (Bartel et al., 1996;Schwinger et al.,

44 1999;Sande et al., 2002). Therefore, the increased formation of peroxynitrite that occurs in heart

45 failure may be an important component of the P-AR dysfunction observed in heart failure and

46 other cardiomyopathies. A recent study demonstrated that peroxynitrite was an independent risk

1 predictor of post-operative complications (i.e., atrial fibrillation, need for inotropic support,

2 length of hospital stay) among patients undergoing cardiac surgery for various reasons

3 (Antoniades et al., 2012), further validating the significance of increased peroxynitrite in cardiac

4 dysfunction.

6 Peroxynitrite and mitochondrial function

7 The processes of cardiomyocyte contraction and Ca2+ reuptake/extrusion are dependent

8 upon ATP. Through oxidative phosphorylation, mitochondria produce the majority of the ATP

9 that is necessary for these processes. Ca2+ is also taken up by the mitochondria during each Ca2+

10 transient, and this serves to couple excitation-contraction coupling with energetic demand

11 (Maack and O'Rourke, 2007). Recent work has demonstrated that mitochondrial function is

12 modulated by RNS (i.e., NO, peroxynitrite).

14 NO is a well established physiological mediator of mitochondrial respiration, and these

15 effects primarily result from the inhibition of Complex I and IV of the electron transport chain

16 (Brookes, 2004). Although Complex I and IV are similarly inhibited by NO, this inhibition

17 occurs through two distinct mechanisms. In the case of Complex I, NO acts via ^-nitrosylation of

18 the 75 kDa subunit of Complex I (Burwell et al., 2006). Complex IV, on the other hand, is

19 inhibited through the reaction of NO with the catalytic metals located in the active site of

20 cytochrome c oxidase (Cleeter et al., 1994;Palacios-Callender et al., 2004). NO can also target

21 additional mitochondrial proteins by reacting with superoxide to yield peroxynitrite. The effects

22 of peroxynitrite on mitochondrial function are much less defined when compared to those of NO,

23 but peroxynitrite has the potential to signal physiologically in the mitochondria or to contribute

24 to mitochondrial dysfunction during pathological states.

26 Peroxynitrite has been shown to target many different proteins in the mitochondria and

27 this can occur via ^-nitrosylation, as reported to occur with Complex I of the electron transport

28 chain (Borutaite et al., 2000), or through irreversible nitration and/or cysteine oxidation. The

29 reversibility of ^-nitrosylation may represent a potential physiological signaling pathway for

30 peroxynitrite in the mitochondria, while the effects of irreversible nitration and cysteine

31 oxidation are likely to be highly detrimental to mitochondrial function. For example,

32 peroxynitrite induced the irreversible inhibition of mitochondrial creatine kinase, and this effect

33 could not be reversed with GSH treatment (Konorev et al., 1998). Peroxynitrite was also shown

34 to inactivate the Kreb's cycle enzyme aconitase (Castro et al., 1994). Additional mitochondrial

35 targets of peroxynitrite include the adenine nucleotide translocase (Vieira et al., 2001),

36 nicotinamide nucleotide transhydrogenase (Forsmark-Andree et al., 1996), and Complex I, II ,

37 and V of the electron transport chain (Radi et al., 1994;Cassina and Radi, 1996;Riobo et al.,

38 2001). Manganese superoxide dismutase, which is a major enzyme for the decomposition of

39 superoxide in the mitochondria, is another target of peroxynitrite and is inactivated via nitration

40 (Quijano et al., 2001). This peroxynitrite-induced inactivation is further compounded by

41 increased levels of superoxide, which could in turn, lead to the formation of additional

42 peroxynitrite. Hence, a decrease in energy supply by inhibiting mitochondrial function could

43 contribute to the depressed contractile function associated with high levels of peroxynitrite.

45 Low vs High levels of Peroxynitrite

1 Peroxynitrite has a biphasic effect on cardiomyocyte contraction, which is mainly

2 concentration dependent (low vs high). However, since peroxynitrite is highly reactive and

3 rapidly decomposed, accurate measurements of concentration are difficult. In addition,

4 determining intracellular concentrations of peroxynitrite with exogenously applied authentic

5 peroxynitrite or the peroxynitrite donor SIN-1 is challenging, making direct comparisons to

6 endogenously produced peroxynitrite formidable. In general, concentrations of 30 ^M or less of

7 authentic peroxynitrite or 100 ^M or less of SIN-1 will result in positive inotropic effects as

8 described. We have previously reported that 10 ^M SIN-1 produces 3 nM/min peroxynitrite in

9 our physiological saline solution (Kohr et al., 2008a). Higher concentrations (100 ^.M authentic

10 peroxynitrite or 200 ^M SIN-1) will result in negative inotropic effects as described. We have

11 previously reported that 200 ^M SIN-1 results in a 6X greater production of peroxynitrite

12 compared to 10 ^M SIN-1 (Kohr et al., 2008b). We consider these levels to be physiologically

13 and pathophysiologically relevant as we and others observed similar effects on function in

14 studies investigating NOS1 and NOS2 signaling. Thus, these concentrations of peroxynitrite

15 result in the activation of various signaling pathways (PKA, PP2A, S-nitrosylation, etc.) resulting

16 in the enhancement or reduction of myocardial contractility. There have been exceptions

17 reported in which low concentrations of authentic peroxynitrite/SIN-1 resulted in negative

18 inotropic effects or high concentrations of SIN-1 resulted in positive inotropic effects (Yin et al.,

19 2002;Katori et al., 2006;Kohr et al., 2008a). Thus other factors also contribute to the contractile

20 effects of peroxynitrite such as cardiomyocyte contractile state, signaling pathway activation

21 (e.g., S-nitrosylation, nitration, cGMP or cAMP) as well as the length of exposure (Schulz et al.,

22 1997;Ziolo, 2008).

23 Studies have also been performed using very high concentrations of authentic

24 peroxynitrite (mM) or long exposure times. These studies revealed irreversible effects of

25 peroxynitrite that depressed myocyte contraction and inactivated SERCA. (Ishida et al.,

26 1996;Knyushko et al., 2005;Lokuta et al., 2005). A consequence of this very high concentration

27 of peroxynitrite is likely a toxic effect that results in cell damage. For example, peroxynitrite is

28 able to activate matrix metalloproteinases that will result in the cleavage of a-actinin and TnI

29 (Wang et al., 2002;Rork et al., 2006;Sung et al., 2007;Leon et al., 2008). We believe that very

30 high concentrations of peroxynitrite can be produced in certain disease states such as heart

31 failure or ischemia/reperfusion injury which have reported SERCA inactivation via nitration or

32 TnI cleavage.

34 In conclusion, peroxynitrite is emerging as a crucial modulator of myocardial function

35 during health and disease. Under physiological conditions, low levels of peroxynitrite serve to

36 maintain and/or increase basal and P-AR-stimulated contraction in the myocardium. This occurs

37 via RyR and PLB phosphorylation through direct PKA activation and SERCA activation via S-

38 nitrosylation (Figure 1). Conversely, supraphysiological levels of peroxynitrite (due to NOS2

39 expression and increased ROS levels via NADPH oxidase and xanthine oxidase) are detrimental

40 to myocardial function and decrease P-AR-stimulated cardiomyocyte contraction. This occurs

41 via PLB dephosphorylation through PP2a activation, decreased RyR activity, mitochondrial

42 dysfunction and myofilament protein cleavage (Figure 2). This dual effect lends critical insight

43 into the physiological and pathophysiological regulation of myocardial contraction by

44 peroxynitrite.

5 FIGURE 1

9 Figure 1. Physiological signaling pathway of low peroxynitrite. This is a diagrammatic

10 representation of low peroxynitrite signaling and various proposed end targets within the

11 cardiomyocyte. The endogenous production of low peroxynitrite can occur via NOS1/xanthine

12 oxidase.

1 FIGURE 2

5 Figure 2. Pathophysiological signaling pathway of high peroxynitrite. This is a diagrammatic

6 representation of high peroxynitrite signaling and various proposed end targets within the

7 cardiomyocyte. The endogenous production of high levels of peroxynitrite can occur via

8 NOS2/NADPH oxidase/xanthine oxidase.

9 10 11

1 Acknowledgements

2 Supported by the American Heart Association (Pre-doctoral Fellowship 0715159B, MJK) and

3 the National Institutes of Health (K02HL094692, R01HL079283, MTZ; R01HL38324,

4 HL63744, HL65608, JLZ).

8 References

10 Akhtar, M.J., Bonner, F.T., and Hughes, M.N. (1985). Reaction of nitric oxide with hyponitrous

11 acid: a hyrdogen atom abstraction reaction. Inorg Chem 24, 1934-1935.

12 Antoniades, C., Demosthenous, M., Reilly, S., Margaritis, M., Zhang, M.H., Antonopoulos, A.,

13 Marinou, K., Nahar, K., Jayaram, R., Tousoulis, D., Bakogiannis, C., Sayeed, R.,

14 Triantafyllou, C., Koumallos, N., Psarros, C., Miliou, A., Stefanadis, C., Channon, K.M.,

15 and Casadei, B. (2012). Myocardial redox state predicts in-hospital clinical outcome after

16 cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol 59,

17 60-70.

18 Arstall, M.A., Sawyer, D.B., Fukazawa, R., and Kelly, R.A. (1999). Cytokine-mediated

19 apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and

20 peroxynitrite generation. Circ Res. 85, 829-840.

21 Balligand, J.L., Kelly, R.A., Marsden, P.A., Smith, T.W., and Michel, T. (1993). Control of

22 cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl

23 AcadSci USA. 90, 347-351.

24 Barouch, L.A., Harrison, R.W., Skaf, M.W., Rosas, G.O., Cappola, T.P., Kobeissi, Z.A., Hobai,

25 I.A., Lemmon, C.A., Burnett, A.L., O'rourke, B., Rodriguez, E.R., Huang, P.L., Lima,

26 J.A., Berkowitz, D.E., and Hare, J.M. (2002). Nitric oxide regulates the heart by spatial

27 confinement of nitric oxide synthase isoforms. Nature. 416, 337-339.

28 Bartel, S., Stein, B., Eschenhagen, T., Mende, U., Neumann, J., Schmitz, W., Krause, E.G.,

29 Karczewski, P., and Scholz, H. (1996). Protein phosphorylation in isolated trabeculae

30 from nonfailing and failing human hearts. Mol CellBiochem. 157, 171-179.

31 Bassani, J.W., Yuan, W., and Bers, D.M. (1995). Fractional SR Ca release is regulated by trigger

32 Ca and SR Ca content in cardiac myocytes. Am J Physiol. 268, C1313-1319.

33 Beckman, J.S., and Koppenol, W.H. (1996). Nitric oxide, superoxide, and peroxyni trite: the

34 good, the bad, and ugly. Am J Physiol. 271, C1424-1437.

35 Bencsik, P., Kupai, K., Giricz, Z., Gorbe, A., Huliak, I., Furst, S., Dux, L., Csont, T., Jancso, G.,

36 and Ferdinandy, P. (2008). Cardiac capsaicin-sensitive sensory nerves regulate

37 myocardial relaxation via S-nitrosylation of SERCA: role of peroxynitrite. Br J

38 Pharmacol. 153, 488-496.

1 Bers, D.M. (2001). Excitation-Contraction Coupling and Cardiac Contractile Force. Dordrecht,

2 The Netherlands: Kluwer Academic Publishers.

3 Bers, D.M. (2002). Cardiac excitation-contraction coupling. Nature. 415, 198-205.

4 Bers, D.M., and Ziolo, M.T. (2001). When is cAMP not cAMP? Effects of

5 compartmentalization. Circ Res. 89, 373-375.

6 Bhattacharyya, J., Biswas, S., and Datta, A.G. (2004). Mode of action of endotoxin: role of free

7 radicals and antioxidants. Curr Med Chem. 11, 359-368.

8 Boknik, P., Fockenbrock, M., Herzig, S., Knapp, J., Linck, B., Luss, H., Muller, F.U., Muller, T.,

9 Schmitz, W., Schroder, F., and Neumann, J. (2000). Protein phosphatase activity is

10 increased in a rat model of long-term beta-adrenergic stimulation. Naunyn Schmiedebergs

11 Arch Pharmacol. 362, 222-231.

12 Borutaite, V., Budriunaite, A., and Brown, G.C. (2000). Reversal of nitric oxide-, peroxynitrite-

13 and S-nitrosothiol-induced inhibition of mitochondrial respiration or complex I activity

14 by light and thiols. Biochim Biophys Acta 1459, 405-412.

15 Brennan, J.P., Bardswell, S.C., Burgoyne, J.R., Fuller, W., Schroder, E., Wait, R., Begum, S.,

16 Kentish, J.C., and Eaton, P. (2006). Oxidant-induced activation of type I protein kinase A

17 is mediated by RI subunit interprotein disulfide bond formation. J Biol Chem. 281,

18 21827-21836.

19 Brito, C., Naviliat, M., Tiscornia, A.C., Vuillier, F., Gualco, G., Dighiero, G., Radi, R., and

20 Cayota, A.M. (1999). Peroxynitrite inhibits T lymphocyte activation and proliferation by

21 promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic

22 death. J Immunol. 162, 3356-3366.

23 Brookes, P.S. (2004). Mitochondrial nitric oxide synthase. Mitochondrion 3, 187-204.

24 Burgoyne, J.R., and Eaton, P. (2009). Transnitrosylating nitric oxide species directly activate

25 type I protein kinase A, providing a novel adenylate cyclase-independent cross-talk to

26 beta-adrenergic-like signaling. J Biol Chem. 284, 29260-29268.

27 Burwell, L S., Nadtochiy, S.M., Tompkins, A.J., Young, S., and Brookes, P.S. (2006). Direct

28 evidence for S-nitrosation of mitochondrial complex I. Biochem J 394, 627-634.

29 Buttery, L.D., Springall, D.R., Chester, A.H., Evans, T.J., Standfield, E.N., Parums, D.V.,

30 Yacoub, M.H., and Polak, J.M. (1996). Inducible nitric oxide synthase is present within

31 human atherosclerotic lesions and promotes the formation and activity of peroxynitrite.

32 Lab Invest. 75, 77-85.

33 Buys, E.S., Raher, M.J., Blake, S.L., Neilan, T.G., Graveline, A.R., Passeri, J.J., Llano, M.,

34 Perez-Sanz, T.M., Ichinose, F., Janssens, S., Zapol, W.M., Picard, M.H., Bloch, K.D.,

35 and Scherrer-Crosbie, M. (2007). Cardiomyocyte-restricted restoration of nitric oxide

synthase 3 attenuates left ventricular remodeling after chronic pressure overload. Am J Physiol Heart Circ Physiol. 293, H620-627.

3 Byrne, J.A., Grieve, D.J., Cave, A.C., and Shah, A.M. (2003). Oxidative stress and heart failure.

4 Arch Mal Coeur Vaiss 96, 214-221.

5 Cassina, A., and Radi, R. (1996). Differential inhibitory action of nitric oxide and peroxynitrite

6 on mitochondrial electron transport. Arch Biochem Biophys 328, 309-316.

7 Castro, L., Rodriguez, M., and Radi, R. (1994). Aconitase is readily inactivated by peroxynitrite,

8 but not by its precursor, nitric oxide. J Biol Chem 269, 29409-29415.

9 Chen, W., Druhan, L.J., Chen, C.A., Hemann, C., Chen, Y.R., Berka, V., Tsai, A.L., and Zweier,

10 J.L. Peroxynitrite induces destruction of the tetrahydrobiopterin and heme in endothelial

11 nitric oxide synthase: transition from reversible to irreversible enzyme inhibition.

12 Biochemistry 49, 3129-3137.

13 Chesnais, J.M., Fischmeister, R., and Mery, P.F. (1999a). Peroxynitrite is a positive inotropic

14 agent in atrial and ventricular fibres of the frog heart. J Physiol. 521, 375-388.

15 Chesnais, J.M., Fischmeister, R., and Mery, P.F. (1999b). Positive and negative inotropic effects

16 of NO donors in atrial and ventricular fibres of the frog heart. J Physiol. 518, 449-461.

17 Cheung, P.Y., Wang, W., and Schulz, R. (2000). Glutathione protects against myocardial

18 ischemia-reperfusion injury by detoxifying peroxynitrite. J Mol Cell Cardiol. 32, 166919 1678.

20 Chu, G., Lester, J.W., Young, K.B., Luo, W., Zhai, J., and Kranias, E.G. (2000). A single site

21 (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac

22 responses to beta -agonists. J Biol Chem 275, 38938-38943.

23 Cleeter, M.W., Cooper, J.M., Darley-Usmar, V.M., Moncada, S., and Schapira, AH. (1994).

24 Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial

25 respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett

26 345, 50-54.

27 Crow, J.P., Beckman, J.S., and Mccord, J.M. (1995). Sensitivity of the essential zinc-thiolate

28 moiety of yeast alcohol dehydrogenase to hypochlorite and peroxynitrite. Biochemistry.

29 34, 3544-3552.

30 Damy, T., Ratajczak, P., Robidel, E., Bendall, J.K., Oliviero, P., Boczkowski, J., Ebrahimian, T.,

31 Marotte, F., Samuel, J.L., and Heymes, C. (2003). Up-regulation of cardiac nitric oxide

32 synthase 1-derived nitric oxide after myocardial infarction in senescent rats. Faseb J. 17,

33 1934-1936.

34 Damy, T., Ratajczak, P., Shah, A.M., Camors, E., Marty, I., Hasenfuss, G., Marotte, F., Samuel,

35 J.L., and Heymes, C. (2004). Increased neuronal nitric oxide synthase-derived NO

36 production in the failing human heart. Lancet. 363, 1365-1367.

1 Davis, J.P., and Tikunova, S.B. (2008). Ca(2+) exchange with troponin C and cardiac muscle

2 dynamics. Cardiovasc Res 77, 619-626.

3 Denicola, A., Souza, J.M., and Radi, R. (1998). Diffusion of peroxynitrite across erythrocyte

4 membranes. Proc Natl Acad Sci U S A. 95, 3566-3571.

5 Dhar, A., Kaundal, R.K., and Sharma, S.S. (2006). Neuroprotective effects of FeTMPyP: a

6 peroxynitrite decomposition catalyst in global cerebral ischemia model in gerbils.

7 Pharmacol Res. 54, 311-316.

8 Drexler, H., Kastner, S., Strobel, A., Studer, R., Brodde, O.E., and Hasenfuss, G. (1998).

9 Expression, activity and functional significance of inducible nitric oxide synthase in the

10 failing human heart. J Am Coll Cardiol. 32, 955-963.

11 Feldman, D.S., Elton, T.S., Sun, B., Martin, M.M., and Ziolo, M.T. (2008). Mechanisms of

12 disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat Clin

13 Pract Cardiovasc Med. 5, 208-218.

14 Ferdinandy, P. (2006). Peroxynitrite: just an oxidative/nitrosative stressor or a physiological

15 regulator as well? Br J Pharmacol. 148, 1-3.

16 Ferdinandy, P., Danial, H., Ambrus, I., Rothery, R.A., and Schulz, R. (2000). Peroxynitrite is a

17 major contributor to cytokine-induced myocardial contractile failure. Circ Res. 87, 24118 247.

19 Ferdinandy, P., Panas, D., and Schulz, R. (1999). Peroxynitrite contributes to spontaneous loss of

20 cardiac efficiency in isolated working rat hearts. Am J Physiol. 276, H1861-1867.

21 Forsmark-Andree, P., Persson, B., Radi, R., Dallner, G., and Ernster, L. (1996). Oxidative

22 modification of nicotinamide nucleotide transhydrogenase in submitochondrial particles:

23 effect of endogenous ubiquinol. Arch Biochem Biophys 336, 113-120.

24 Gilad, E., Zingarelli, B., Salzman, A.L., and Szabo, C. (1997). Protection by inhibition of poly

25 (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts In vitro. JMol Cell

26 Cardiol. 29, 2585-2597.

27 Hagemann, D., and Xiao, R.P. (2002). Dual site phospholamban phosphorylation and its

28 physiological relevance in the heart. Trends Cardiovasc Med. 12, 51-56.

29 Handy, D.E., and Loscalzo, J. (2006). Nitric oxide and posttranslational modification of the

30 vascular proteome: S-nitrosation of reactive thiols. Arterioscler Thromb Vasc Biol. 26,

31 1207-1214.

32 Hess, D.T., Matsumoto, A., Kim, S.O., Marshall, H.E., and Stamler, J.S. (2005). Protein S-

33 nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 6, 150-166.

1 Heymes, C., Bendall, J.K., Ratajczak, P., Cave, A.C., Samuel, J.L., Hasenfuss, G., and Shah,

2 A.M. (2003). Increased myocardial NADPH oxidase activity in human heart failure. J Am

3 Coll Cardiol. 41, 2164-2171.

4 Houser, S.R., Piacentino, V., 3rd, and Weisser, J. (2000). Abnormalities of calcium cycling in

5 the hypertrophied and failing heart. J Mol Cell Cardiol. 32, 1595-1607.

6 Huie, R.E., and Padmaja, S. (1993). The reaction of no with superoxide. Free Radic Res

7 Commun. 18, 195-199.

8 Ishida, H., Ichimori, K., Hirota, Y., Fukahori, M., and Nakazawa, H. (1996). Peroxynitrite-

9 induced cardiac myocyte injury. Free Radic Biol Med 20, 343-350.

10 Ishimura, Y., Gao, Y.T., Panda, S.P., Roman, L.J., Masters, B.S., and Weintraub, S.T. (2005).

11 Detection of nitrous oxide in the neuronal nitric oxide synthase reaction by gas

12 chromatography-mass spectrometry. Biochem Biophys Res Commun. 338, 543-549.

13 Janssens, S., Pokreisz, P., Schoonjans, L., Pellens, M., Vermeersch, P., Tjwa, M., Jans, P.,

14 Scherrer-Crosbie, M., Picard, M.H., Szelid, Z., Gillijns, H., Van De Werf, F., Collen, D.,

15 and Bloch, K.D. (2004). Cardiomyocyte-specific overexpression of nitric oxide synthase

16 3 improves left ventricular performance and reduces compensatory hypertrophy after

17 myocardial infarction. Circ Res. 94, 1256-1262.

18 Kamat, J.P. (2006). Peroxynitrite: a potent oxidizing and nitrating agent. Indian J Exp Biol. 44,

19 436-447.

20 Katori, T., Donzelli, S., Tocchetti, C.G., Miranda, K.M., Cormaci, G., Thomas, D.D., Ketner,

21 E.A., Lee, M.J., Mancardi, D., Wink, D.A., Kass, D.A., and Paolocci, N. (2006).

22 Peroxynitrite and myocardial contractility: in vivo versus in vitro effects. Free Radic Biol

23 Med. 41, 1606-1618.

24 Khan, S.A., Lee, K., Minhas, K.M., Gonzalez, D.R., Raju, S.V., Tejani, A.D., Li, D., Berkowitz,

25 D.E., and Hare, J.M. (2004). Neuronal nitric oxide synthase negatively regulates xanthine

26 oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci

27 U S A 101, 15944-15948.

28 Khan, S.A., Skaf, M.W., Harrison, R.W., Lee, K., Minhas, K.M., Kumar, A., Fradley, M.,

29 Shoukas, A.A., Berkowitz, D.E., and Hare, J.M. (2003). Nitric oxide regulation of

30 myocardial contractility and calcium cycling: independent impact of neuronal and

31 endothelial nitric oxide synthases. Circ Res. 92, 1322-1329.

32 Kirsch, M., and De Groot, H. (2002). Formation of peroxynitrite from reaction of nitroxyl anion

33 with molecular oxygen. J Biol Chem. 277, 13379-13388.

34 Knyushko, T.V., Sharov, V.S., Williams, T.D., Schoneich, C., and Bigelow, D.J. (2005). 335 Nitrotyrosine modification of SERCA2a in the aging heart: a distinct signature of the 36 cellular redox environment. Biochemistry. 44, 13071-13081.

1 Kohr, M.J., Aponte, A.M., Sun, J., Wang, G., Murphy, E., Gucek, M., and Steenbergen, C.

2 (2011a). Characterization of Potential S-nitrosylation Sites in the Myocardium. Am J

3 Physiol Heart Circ Physiol.

4 Kohr, M.J., Davis, J.D., and Ziolo, M.T. (2009). Peroxynitrite increases protein phosphatase

5 activity and promotes the interaction of phospholamban with protein phosphatase 2a in

6 the myocardium. Nitric Oxide doi: 10.1016/j.niox.2009.01.003.

7 Kohr, M.J., Sun, J., Aponte, A., Wang, G., Gucek, M., Murphy, E., and Steenbergen, C. (2011b).

8 Simultaneous measurement of protein oxidation and S-nitrosylation during

9 preconditioning and ischemia/reperfusion injury with resin-assisted capture. Circ Res

10 108, 418-426.

11 Kohr, M.J., Traynham, C.J., Roof, S.R., Davis, J.P., and Ziolo, M.T. (2010). cAMP-independent

12 activation of protein kinase A by the peroxynitrite generator SIN-1 elicits positive

13 inotropic effects in cardiomyocytes. J Mol Cell Cardiol 48, 645-648.

14 Kohr, M.J., Wang, H., Wheeler, D.G., Velayutham, M., Zweier, J.L., and Ziolo, M.T. (2008a).

15 Biphasic effect of SIN-1 is reliant upon cardiomyocyte contractile state. Free Radic Biol

16 Med. 45, 73-80.

17 Kohr, M.J., Wang, H., Wheeler, D.G., Velayutham, M., Zweier, J.L., and Ziolo, M.T. (2008b).

18 Targeting of phospholamban by peroxynitrite decreases (beta)-adrenergic stimulation in

19 cardiomyocytes. Cardiovasc Res. 77, 353-361.

20 Konorev, E.A., Hogg, N., and Kalyanaraman, B. (1998). Rapid and irreversible inhibition of

21 creatine kinase by peroxynitrite. FEBS Lett 427, 171-174.

22 Leon, H., Baczko, I., Sawicki, G., Light, P.E., and Schulz, R. (2008). Inhibition of matrix

23 metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated

24 cardiac myocyte. Br J Pharmacol 153, 676-683.

25 Levrand, S., Vannay-Bouchiche, C., Pesse, B., Pacher, P., Feihl, F., Waeber, B., and Liaudet, L.

26 (2006). Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo.

27 Free Radic Biol Med. 41, 886-895.

28 Li, L., Desantiago, J., Chu, G., Kranias, E.G., and Bers, D.M. (2000). Phosphorylation of

29 phospholamban and troponin I in beta-adrenergic-induced acceleration of cardiac

30 relaxation. Am J Physiol Heart Circ Physiol. 278, H769-779.

31 Lin, H.L., Myshkin, E., Waskell, L., and Hollenberg, P.F. (2007). Peroxynitrite inactivation of

32 human cytochrome P450s 2B6 and 2E1: heme modification and site-specific

33 nitrotyrosine formation. Chem Res Toxicol. 20, 1612-1622.

34 Lokuta, A.J., Maertz, N.A., Meethal, S.V., Potter, K.T., Kamp, T.J., Valdivia, H.H., and

35 Haworth, R.A. (2005). Increased nitration of sarcoplasmic reticulum Ca2+-ATPase in

36 human heart failure. Circulation. 111, 988-995.

1 Lopez, B.L., Liu, G.L., Christopher, T.A., and Ma, X.L. (1997). Peroxynitrite, the product of

2 nitric oxide and superoxide, causes myocardial injury in the isolated perfused rat heart.

3 Coron Artery Dis. 8, 149-153.

4 Luoma, J.S., Stralin, P., Marklund, S.L., Hiltunen, T.P., Sarkioja, T., and Yla-Herttuala, S.

5 (1998). Expression of extracellular SOD and iNOS in macrophages and smooth muscle

6 cells in human and rabbit atherosclerotic lesions: colocalization with epitopes

7 characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb

8 Vasc Biol. 18, 157-167.

9 Ma, X.L., Lopez, B.L., Liu, G.L., Christopher, T.A., and Ischiropoulos, H. (1997). Peroxynitrite

10 aggravates myocardial reperfusion injury in the isolated perfused rat heart. Cardiovasc

11 Res. 36, 195-204.

12 Maack, C., and O'rourke, B. (2007). Excitation-contraction coupling and mitochondrial

13 energetics. Basic Res Cardiol 102, 369-392.

14 Macdougall, L.K., Jones, L.R., and Cohen, P. (1991). Identification of the major protein

15 phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur

16 J Biochem. 196, 725-734.

17 Macmicking, J., Xie, Q.W., and Nathan, C. (1997). Nitric oxide and macrophage function. Annu

18 Rev Immunol. 15, 323-350.

19 Martinez-Ruiz, A., and Lamas, S. (2004). S-nitrosylation: a potential new paradigm in signal

20 transduction. Cardiovasc Res. 62, 43-52.

21 Mattiazzi, A., Mundina-Weilenmann, C., Vittone, L., Said, M., and Kranias, E.G. (2006). The

22 importance of the Thr17 residue of phospholamban as a phosphorylation site under

23 physiological and pathological conditions. Braz J Med Biol Res. 39, 563-572.

24 Mihm, M.J., Coyle, C.M., Schanbacher, B.L., Weinstein, D.M., and Bauer, J.A. (2001).

25 Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in

26 experimental heart failure. Cardiovasc Res. 49, 798-807.

27 Minhas, K.M., Saraiva, R.M., Schuleri, K.H., Lehrke, S., Zheng, M., Saliaris, A.P., Berry, C.E.,

28 Barouch, L.A., Vandegaer, K.M., Li, D., and Hare, J.M. (2006). Xanthine oxidoreductase

29 inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res. 98,

30 271-279.

31 Mungrue, I.N., Gros, R., You, X., Pirani, A., Azad, A., Csont, T., Schulz, R., Butany, J., Stewart,

32 D.J., and Husain, M. (2002). Cardiomyocyte overexpression of iNOS in mice results in

33 peroxynitrite generation, heart block, and sudden death. J Clin Invest. 109, 735-743.

34 Nathan, C., and Shiloh, M.U. (2000). Reactive oxygen and nitrogen intermediates in the

35 relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S

36 A. 97, 8841-8848.

1 Pacher, P., Beckman, J.S., and Liaudet, L. (2007). Nitric oxide and peroxynitrite in health and

2 disease. Physiol Rev. 87, 315-424.

3 Pacher, P., Liaudet, L., Mabley, J., Komjati, K., and Szabo, C. (2002). Pharmacologic inhibition

4 of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic

5 approach in chronic heart failure. J Am Coll Cardiol. 40, 1006-1016.

6 Palacios-Callender, M., Quintero, M., Hollis, V.S., Springett, R.J., and Moncada, S. (2004).

7 Endogenous NO regulates superoxide production at low oxygen concentrations by

8 modifying the redox state of cytochrome c oxidase. Proc Natl Acad Sci U S A 101, 76309 7635.

10 Paolocci, N., Ekelund, U.E., Isoda, T., Ozaki, M., Vandegaer, K., Georgakopoulos, D., Harrison,

11 R.W., Kass, D.A., and Hare, J.M. (2000). cGMP-independent inotropic effects of nitric

12 oxide and peroxynitrite donors: potential role for nitrosylation. Am J Physiol Heart Circ

13 Physiol. 279, H1982-1988.

14 Pietraforte, D., Salzano, A.M., Scorza, G., Marino, G., and Minetti, M. (2001). Mechanism of

15 peroxynitrite interaction with ferric hemoglobin and identification of nitrated tyrosine

16 residues. CO(2) inhibits heme-catalyzed scavenging and isomerization. Biochemistry. 40,

17 15300-15309.

18 Pou, S., Pou, W.S., Bredt, D.S., Snyder, S.H., and Rosen, G.M. (1992). Generation of superoxide

19 by purified brain nitric oxide synthase. J Biol Chem. 267, 24173-24176.

20 Quijano, C., Hernandez-Saavedra, D., Castro, L., Mccord, J.M., Freeman, B.A., and Radi, R.

21 (2001). Reaction of peroxynitrite with Mn-superoxide dismutase. Role of the metal center

22 in decomposition kinetics and nitration. J Biol Chem 276, 11631-11638.

23 Radi, R., Beckman, J.S., Bush, K.M., and Freeman, B.A. (1991a). Peroxynitrite-induced

24 membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch

25 Biochem Biophys. 288, 481-487.

26 Radi, R., Beckman, J.S., Bush, K.M., and Freeman, B.A. (1991b). Peroxynitrite oxidation of

27 sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem. 266,

28 4244-4250.

29 Radi, R., Cassina, A., and Hodara, R. (2002a). Nitric oxide and peroxynitrite interactions with

30 mitochondria. Biol Chem. 383, 401-409.

31 Radi, R., Cassina, A., Hodara, R., Quijano, C., and Castro, L. (2002b). Peroxynitrite reactions

32 and formation in mitochondria. Free Radic Biol Med. 33, 1451-1464.

33 Radi, R., Rodriguez, M., Castro, L., and Telleri, R. (1994). Inhibition of mitochondrial electron

34 transport by peroxynitrite. Arch Biochem Biophys 308, 89-95.

1 Riobo, N.A., Clementi, E., Melani, M., Boveris, A., Cadenas, E., Moncada, S., and Poderoso, J.J.

2 (2001). Nitric oxide inhibits mitochondrial NADH:ubiquinone reductase activity through

3 peroxynitrite formation. Biochem J 359, 139-145.

4 Roof, SR., Biesiadecki, B.J., Davis, J.P., Janssen, P.M., and Ziolo, M.T. (2012). Effects of

5 increased systolic Ca(2+) and beta-adrenergic stimulation on Ca(2+) transient decline in

6 NOS1 knockout cardiac myocytes. Nitric Oxide, In Press.

7 Roof, S.R., Shannon, T.R., Janssen, P.M., and Ziolo, M.T. (2011). Effects of increased systolic

8 Ca2+ and phospholamban phosphorylation during beta-adrenergic stimulation on Ca2+

9 transient kinetics in cardiac myocytes. Am J Physiol Heart Circ Physiol 301, H1570-

10 1578.

11 Rork, T.H., Hadzimichalis, N.M., Kappil, M.A., and Merrill, G.F. (2006). Acetaminophen

12 attenuates peroxynitrite-activated matrix metalloproteinase-2-mediated troponin I

13 cleavage in the isolated guinea pig myocardium. J Mol Cell Cardiol. 40, 553-561.

14 Sande, J.B., Sjaastad, I., Hoen, I.B., Bokenes, J., Tonnessen, T., Holt, E., Lunde, P.K., and

15 Christensen, G. (2002). Reduced level of serine(16) phosphorylated phospholamban in

16 the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc

17 Res. 53, 382-391.

18 Schildknecht, S., Van Der Loo, B., Weber, K., Tiefenthaler, K., Daiber, A., and Bachschmid,

19 M.M. (2008). Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2

20 formation and aggregation in human platelets. Free Radic Biol Med. 45, 512-520.

21 Schmidt, H.H., Hofmann, H., Schindler, U., Shutenko, Z.S., Cunningham, D.D., and Feelisch,

22 M. (1996). No .NO from NO synthase. Proc Natl Acad Sci U S A. 93, 14492-14497.

23 Schulz, R., Dodge, K.L., Lopaschuk, G.D., and Clanachan, A.S. (1997). Peroxynitrite impairs

24 cardiac contractile function by decreasing cardiac efficiency. Am J Physiol 272, H1212-

25 1219.

26 Schulz, R., Nava, E., and Moncada, S. (1992). Induction and potential biological relevance of a

27 Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol 105, 57528 580.

29 Schwinger, R.H., Munch, G., Bolck, B., Karczewski, P., Krause, E.G., and Erdmann, E. (1999).

30 Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced

31 serin-16 phospholamban phosphorylation. J Mol Cell Cardiol. 31, 479-491.

32 Shan, J., Kushnir, A., Betzenhauser, M.J., Reiken, S., Li, J., Lehnart, S.E., Lindegger, N.,

33 Mongillo, M., Mohler, P.J., and Marks, A.R. (2010). Phosphorylation of the ryanodine

34 receptor mediates the cardiac fight or flight response in mice. J Clin Invest 120, 438835 4398.

1 Sommer, D., Coleman, S., Swanson, S.A., and Stemmer, P.M. (2002). Differential

2 susceptibilities of serine/threonine phosphatases to oxidative and nitrosative stress. Arch

3 Biochem Biophys. 404, 271-278.

4 Stojanovic, M.O., Ziolo, M.T., Wahler, G.M., and Wolska, B.M. (2001). Anti-adrenergic effects

5 of nitric oxide donor SIN-1 in rat cardiac myocytes. Am J Physiol Cell Physiol. 281,

6 C342-349.

7 Suarez-Pinzon, W.L., Mabley, J.G., Strynadka, K., Power, R.F., Szabo, C., and Rabinovitch, A.

8 (2001). An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite

9 prevents diabetes development in NOD mice. J Autoimmun. 16, 449-455.

10 Suarez-Pinzon, W.L., Szabo, C., and Rabinovitch, A. (1997). Development of autoimmune

11 diabetes in NOD mice is associated with the formation of peroxynitrite in pancreatic islet

12 beta-cells. Diabetes. 46, 907-911.

13 Sun, J., Druhan, L.J., and Zweier, J.L. (2008). Dose dependent effects of reactive oxygen and

14 nitrogen species on the function of neuronal nitric oxide synthase. Arch Biochem

15 Biophys. 471, 126-133.

16 Sung, M.M., Schulz, C.G., Wang, W., Sawicki, G., Bautista-Lopez, N.L., and Schulz, R. (2007).

17 Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in

18 peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 43, 429-436.

19 Szabo, C., Ferrer-Sueta, G., Zingarelli, B., Southan, G.J., Salzman, A.L., and Radi, R. (1997).

20 Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with

21 peroxynitrite and protect against peroxynitrite-induced oxidative damage. J Biol Chem.

22 272, 9030-9036.

23 Szabo, C., Zingarelli, B., O'connor, M., and Salzman, A.L. (1996). DNA strand breakage,

24 activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in

25 the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc

26 Natl Acad Sci U S A. 93, 1753-1758.

27 Terentyev, D., Viatchenko-Karpinski, S., Gyorke, I., Terentyeva, R., and Gyorke, S. (2003).

28 Protein phosphatases decrease sarcoplasmic reticulum calcium content by stimulating

29 calcium release in cardiac myocytes. J Physiol 552, 109-118.

30 Thiyagarajan, M., Kaul, C.L., and Sharma, S.S. (2004). Neuroprotective efficacy and therapeutic

31 time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats.

32 Br J Pharmacol. 142, 899-911.

33 Trafford, A.W., Lipp, P., O'neill, S.C., Niggli, E., and Eisner, D A. (1995). Propagating calcium

34 waves initiated by local caffeine application in rat ventricular myocytes. J Physiol. 489,

35 319-326.

1 Tuo, J., Wolff, S.P., Loft, S., and Poulsen, H.E. (1998). Formation of nitrated and hydroxylated

2 aromatic compounds from benzene and peroxynitrite, a possible mechanism of benzene

3 genotoxicity. Free Radic Res. 28, 369-375.

4 Tziomalos, K., and Hare, J.M. (2009). Role of xanthine oxidoreductase in cardiac nitroso-redox

5 imbalance. Front Biosci 14, 237-262.

6 Uppu, R.M., and Pryor, W.A. (1996). Carbon dioxide catalysis of the reaction of peroxynitrite

7 with ethyl acetoacetate: an example of aliphatic nitration by peroxynitrite. Biochem

8 Biophys Res Commun. 229, 764-769.

9 Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T., Mazur, M., and Telser, J. (2007). Free

10 radicals and antioxidants in normal physiological functions and human disease. Int J

11 Biochem Cell Biol. 39, 44-84.

12 Vandsburger, M.H., French, B.A., Helm, P.A., Roy, R.J., Kramer, C.M., Young, A.A., and

13 Epstein, F.H. (2007). Multi-parameter in vivo cardiac magnetic resonance imaging

14 demonstrates normal perfusion reserve despite severely attenuated beta-adrenergic

15 functional response in neuronal nitric oxide synthase knockout mice. Eur Heart J. 28,

16 2792-2798.

17 Vieira, H.L., Belzacq, A.S., Haouzi, D., Bernassola, F., Cohen, I., Jacotot, E., Ferri, K.F., El

18 Hamel, C., Bartle, L.M., Melino, G., Brenner, C., Goldmacher, V., and Kroemer, G.

19 (2001). The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 420 hydroxynonenal. Oncogene 20, 4305-4316.

21 Vig, M., Srivastava, S., Kandpal, U., Sade, H., Lewis, V., Sarin, A., George, A., Bal, V., Durdik,

22 J.M., and Rath, S. (2004). Inducible nitric oxide synthase in T cells regulates T cell death

23 and immune memory. J Clin Invest. 113, 1734-1742.

24 Vila-Petroff, M.G., Younes, A., Egan, J., Lakatta, E.G., and Sollott, S.J. (1999). Activation of

25 distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac

26 myocytes. Circ Res. 84, 1020-1031.

27 Wang, H., Bonilla, I.M., Huang, X., He, Q., Kohr, M.J., Carnes, C.A., and Ziolo, M.T. (2012).

28 Prolonged Action Potential and After Depolarizations Are Not Due to Changes in

29 Potassium Currents in NO S3 Knockout Ventricular Myocytes. J Signal Transduct,

30 645721.

31 Wang, H., Kohr, M.J., Traynham, C.J., Wheeler, D.G., Janssen, P.M., and Ziolo, M.T. (2008a).

32 Neuronal Nitric Oxide Synthase Signaling within Cardiac Myocytes Targets

33 Phospholamban. Am J Physiol Cell Physiol 294, C1566-C1575.

34 Wang, H., Kohr, M.J., Traynham, C.J., and Ziolo, M.T. (2009). Phosphodiesterase 5 restricts

35 NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes. J

36 Mol Cell Cardiol 47, 304-314.

1 Wang, H., Kohr, M.J., Wheeler, D.G., and Ziolo, M.T. (2008b). Endothelial nitric oxide synthase

2 decreases beta-adrenergic responsiveness via inhibition of the L-type Ca2+ current. Am J

3 Physiol Heart Circ Physiol. 294, H1473-1480.

4 Wang, H., Viatchenko-Karpinski, S., Sun, J., Gyorke, I., Benkusky, N.A., Kohr, M.J., Valdivia,

5 H.H., Murphy, E., Gyorke, S., and Ziolo, M.T. (2010). Regulation of myocyte

6 contraction via neuronal nitric oxide synthase: role of ryanodine receptor S-nitrosylation.

7 J Physiol 588, 2905-2917.

8 Wang, P., and Zweier, J.L. (1996). Measurement of nitric oxide and peroxynitrite generation in

9 the postischemic heart. Evidence for peroxynitrite-mediated reperfusion injury. J Biol

10 Chem 271, 29223-29230.

11 Wang, W., Sawicki, G., and Schulz, R. (2002). Peroxynitrite-induced myocardial injury is

12 mediated through matrix metalloproteinase-2. Cardiovasc Res 53, 165-174.

13 Wu, F., and Wilson, J.X. (2009). Peroxynitrite-dependent activation of protein phosphatase type

14 2A mediates microvascular endothelial barrier dysfunction. Cardiovasc Res. 81, 38-45.

15 Xia, Y., Dawson, V.L., Dawson, T.M., Snyder, S.H., and Zweier, J.L. (1996). Nitric oxide

16 synthase generates superoxide and nitric oxide in arginine-depleted cells leading to

17 peroxynitrite-mediated cellular injury. Proc Natl Acad Sci U S A 93, 6770-6774.

18 Xia, Y., Roman, L.J., Masters, B.S., and Zweier, J.L. (1998). Inducible nitric-oxide synthase

19 generates superoxide from the reductase domain. J Biol Chem. 273, 22635-22639.

20 Xia, Y., and Zweier, J.L. (1997). Superoxide and peroxynitrite generation from inducible nitric

21 oxide synthase in macrophages. Proc Natl Acad Sci U S A. 94, 6954-6958.

22 Yin, X., Shan, Q., Deng, C., and Bourreau, J.P. (2002). Effect of SIN-1 in rat ventricular

23 myocytes: interference with beta-adrenergic stimulation. Life Sci 71, 287-297.

24 Zhang, P., Xu, X., Hu, X., Van Deel, E.D., Zhu, G., and Chen, Y. (2007). Inducible nitric oxide

25 synthase deficiency protects the heart from systolic overload-induced ventricular

26 hypertrophy and congestive heart failure. Circ Res. 100, 1089-1098.

27 Zhang, Y.H., Zhang, M.H., Sears, C.E., Emanuel, K., Redwood, C., El-Armouche, A., Kranias,

28 E.G., and Casadei, B. (2008). Reduced phospholamban phosphorylation is associated

29 with impaired relaxation in left ventricular myocytes from neuronal NO synthase-

30 deficient mice. Circ Res. 102, 242-249.

31 Ziolo, M.T. (2008). The fork in the nitric oxide road: cyclic GMP or nitrosylation? Nitric Oxide.

32 18, 153-156.

33 Ziolo, M.T., and Bers, D.M. (2003). The real estate of NOS signaling: location, location,

34 location. Circ Res. 92, 1279-1281.

1 Ziolo, M.T., Dollinger, S.J., and Wahler, G.M. (1998). Myocytes isolated from rejecting

2 transplanted rat hearts exhibit reduced basal shortening which is reversible by

3 aminoguanidine. J Mol Cell Cardiol. 30, 1009-1017.

4 Ziolo, M.T., Harshbarger, C.H., Roycroft, K.E., Smith, J.M., Romano, F.D., Sondgeroth, K.L.,

5 and Wahl er, G.M. (2001a). Myocytes isolated from rejecting transplanted rat hearts

6 exhibit a nitric oxide-mediated reduction in the calcium current. J Mol Cell Cardiol. 33,

7 1691-1699.

8 Ziolo, M.T., Katoh, H., and Bers, D.M. (2001b). Expression of inducible nitric oxide synthase

9 depresses beta-adrenergic-stimulated calcium release from the sarcoplasmic reticulum in

10 intact ventricular myocytes. Circulation. 104, 2961-2966.

11 Ziolo, M.T., Katoh, H., and Bers, D.M. (2001c). Positive and negative effects of nitric oxide on

12 Ca(2+) sparks: influence of beta-adrenergic stimulation. Am J Physiol Heart Circ

13 Physiol. 281, H2295-2303.

14 Ziolo, M.T., Kohr, M.J., and Wang, H. (2008). Nitric oxide signaling and the regulation of

15 myocardial function. J Mol Cell Cardiol. 45, 625-632.

16 Ziolo, M.T., Maier, L.S., Piacentino, V., 3rd, Bossuyt, J., Houser, S.R., and Bers, D.M. (2004).

17 Myocyte nitric oxide synthase 2 contributes to blunted beta-adrenergic response in failing

18 human hearts by decreasing Ca2+ transients. Circulation. 109, 1886-1891.

19 Zou, M.H., Cohen, R., and Ullrich, V. (2004). Peroxynitrite and vascular endothelial dysfunction

20 in diabetes mellitus. Endothelium. 11, 89-97.

21 Zouki, C., Zhang, S.L., Chan, J.S., and Filep, J.G. (2001). Peroxynitrite induces integrin-

22 dependent adhesion of human neutrophils to endothelial cells via activation of the Raf-

23 1/MEK/Erk pathway. Faseb J. 15, 25-27.

Copyright of Frontiers in Physiology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.